Daily Stock Analysis, IDRA, Idera Pharmaceuticals Inc, priceseries

Idera Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.60
Close
2.72
High
2.73
Low
2.58
Previous Close
2.57
Daily Price Gain
0.15
YTD High
3.89
YTD High Date
Jan 7, 2019
YTD Low
2.25
YTD Low Date
Apr 22, 2019
YTD Price Change
-0.80
YTD Gain
-22.73%
52 Week High
17.12
52 Week High Date
May 31, 2018
52 Week Low
2.25
52 Week Low Date
Apr 22, 2019
52 Week Price Change
-9.60
52 Week Gain
-77.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 14. 2017
12.64
Feb 27. 2017
13.28
8 Trading Days
5.06%
Link
LONG
Mar 16. 2017
15.92
Apr 5. 2017
18.71
14 Trading Days
17.53%
Link
LONG
Jun 19. 2017
13.28
Jun 29. 2017
14.12
8 Trading Days
6.33%
Link
LONG
Dec 27. 2017
16.64
Jan 22. 2018
18.37
16 Trading Days
10.37%
Link
LONG
May 9. 2018
13.76
May 21. 2018
14.83
8 Trading Days
7.78%
Link
LONG
Aug 13. 2018
7.39
Aug 20. 2018
7.86
5 Trading Days
6.36%
Link
Company Information
Stock Symbol
IDRA
Exchange
NasdaqCM
Company URL
http://www.iderapharma.com
Company Phone
6176795500
CEO
Vin Milano
Headquarters
Massachusetts
Business Address
167 SIDNEY STREET, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000861838
About

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.

Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.